296 related articles for article (PubMed ID: 35352805)
21. TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in acute myeloid leukemia.
Sakoda T; Kikushige Y; Miyamoto T; Irifune H; Harada T; Hatakeyama K; Kunisaki Y; Kato K; Akashi K
Blood Adv; 2023 May; 7(10):2053-2065. PubMed ID: 36745103
[TBL] [Abstract][Full Text] [Related]
22. GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.
Dietrich PA; Yang C; Leung HH; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY
Blood; 2014 Nov; 124(22):3284-94. PubMed ID: 25293777
[TBL] [Abstract][Full Text] [Related]
23. Exosomal miR92a Promotes Cytarabine Resistance in Myelodysplastic Syndromes by Activating Wnt/β-catenin Signal Pathway.
Li H; Xie C; Lu Y; Chang K; Guan F; Li X
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291656
[TBL] [Abstract][Full Text] [Related]
24. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts.
Kode A; Manavalan JS; Mosialou I; Bhagat G; Rathinam CV; Luo N; Khiabanian H; Lee A; Murty VV; Friedman R; Brum A; Park D; Galili N; Mukherjee S; Teruya-Feldstein J; Raza A; Rabadan R; Berman E; Kousteni S
Nature; 2014 Feb; 506(7487):240-4. PubMed ID: 24429522
[TBL] [Abstract][Full Text] [Related]
25. DIXDC1 promotes the growth of acute myeloid leukemia cells by upregulating the Wnt/β-catenin signaling pathway.
Xin H; Li C; Wang M
Biomed Pharmacother; 2018 Nov; 107():1548-1555. PubMed ID: 30257373
[TBL] [Abstract][Full Text] [Related]
26. Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia.
Chong PSY; Zhou J; Chooi JY; Chan ZL; Toh SHM; Tan TZ; Wee S; Gunaratne J; Zeng Q; Chng WJ
Oncogene; 2019 Feb; 38(9):1508-1519. PubMed ID: 30305722
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological targeting of type phosphodiesterase 4 inhibits the development of acute myeloid leukemia by impairing mitochondrial function through the Wnt/β-catenin pathway.
Mao P; Huang C; Li Y; Zhao Y; Zhou S; Zhao Z; Mu Y; Wang L; Li F; Zhao AZ
Biomed Pharmacother; 2023 Jan; 157():114027. PubMed ID: 36436494
[TBL] [Abstract][Full Text] [Related]
28. LncRNA SNHG1 contributes to the regulation of acute myeloid leukemia cell growth by modulating miR-489-3p/SOX12/Wnt/β-catenin signaling.
Li C; Gao Q; Wang M; Xin H
J Cell Physiol; 2021 Jan; 236(1):653-663. PubMed ID: 32592199
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome.
Xu J; Suzuki M; Niwa Y; Hiraga J; Nagasaka T; Ito M; Nakamura S; Tomita A; Abe A; Kiyoi H; Kinoshita T; Naoe T
Br J Haematol; 2008 Feb; 140(4):394-401. PubMed ID: 18217891
[TBL] [Abstract][Full Text] [Related]
30. "Losing the Brakes"-Suppressed Inhibitors Triggering Uncontrolled
Elyamany G; Rizwan H; Akhter A; Aljabry MS; Alotaibi S; Albalawi MAH; Shabani-Rad MT; Roshan TM; Mansoor A
Curr Issues Mol Biol; 2023 Jan; 45(1):604-613. PubMed ID: 36661526
[TBL] [Abstract][Full Text] [Related]
31. [Beta-catenin and cyclin D1 mRNA levels in newly diagnosed patients with acute myeloid leukemia and their significance].
Wang YX; Zhang JH; Gu ZW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):304-8. PubMed ID: 19379556
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/β-catenin pathway.
Kang Y; Zhang S; Cao W; Wan D; Sun L
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32426817
[TBL] [Abstract][Full Text] [Related]
33. A novel dipeptide type inhibitor of the Wnt/β-catenin pathway suppresses proliferation of acute myelogenous leukemia cells.
Wakabayashi R; Hattori Y; Hosogi S; Toda Y; Takata K; Ashihara E
Biochem Biophys Res Commun; 2021 Jan; 535():73-79. PubMed ID: 33341676
[TBL] [Abstract][Full Text] [Related]
34. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin.
Morgan RG; Pearn L; Liddiard K; Pumford SL; Burnett AK; Tonks A; Darley RL
Leukemia; 2013 Feb; 27(2):336-43. PubMed ID: 22858986
[TBL] [Abstract][Full Text] [Related]
35. SOX30 confers a tumor suppressive effect in acute myeloid leukemia through inactivation of Wnt/β-catenin signaling.
Liu Y; Wang W; Li Y; Huang Y
Mol Cell Probes; 2020 Aug; 52():101578. PubMed ID: 32334007
[TBL] [Abstract][Full Text] [Related]
36. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.
Ysebaert L; Chicanne G; Demur C; De Toni F; Prade-Houdellier N; Ruidavets JB; Mansat-De Mas V; Rigal-Huguet F; Laurent G; Payrastre B; Manenti S; Racaud-Sultan C
Leukemia; 2006 Jul; 20(7):1211-6. PubMed ID: 16688229
[TBL] [Abstract][Full Text] [Related]
37. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.
Fiskus W; Sharma S; Saha S; Shah B; Devaraj SG; Sun B; Horrigan S; Leveque C; Zu Y; Iyer S; Bhalla KN
Leukemia; 2015 Jun; 29(6):1267-78. PubMed ID: 25482131
[TBL] [Abstract][Full Text] [Related]
38. CRIP1 supports the growth and migration of AML-M5 subtype cells by activating Wnt/β-catenin pathway.
Deng X; Zeng Y; Qiu X; Zhong M; Xiong X; Luo M; Zhang J; Chen X
Leuk Res; 2023 Jul; 130():107312. PubMed ID: 37224580
[TBL] [Abstract][Full Text] [Related]
39. Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis.
Feder K; Edmaier-Schröger K; Rawat VPS; Kirsten N; Metzeler K; Kraus JM; Döhner K; Döhner H; Kestler HA; Feuring-Buske M; Buske C
Leukemia; 2020 Apr; 34(4):1027-1037. PubMed ID: 31758089
[TBL] [Abstract][Full Text] [Related]
40. [Expressions of CDX2 and β-catenin and their correlation in acute myeloid leukemia].
Wang W; Meng C; Liu J; Yang Z
Nan Fang Yi Ke Da Xue Xue Bao; 2015 May; 35(5):728-32. PubMed ID: 26018272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
